Beta-O2 Technologies Ltd. and an
international team of academic collaborators have shown that the company's
bioartificial pancreas can house donor islets, supply them with oxygen and
protect them from the host immune system in
vivo for at least three months.1 They also
demonstrated that the minimally invasive implant could normalize blood glucose levels and improve
glycemic control in rat models of diabetes. The team hopes to start a trial of
the implant in a single patient this year.
Lou, K.-J. SciBX 5(12); doi:10.1038/scibx.2012.298
Published online March 22, 2012
1. Ludwig, B. et
al. Proc. Natl. Acad. Sci. USA; published online March 5, 2012;
V. Schally, University of Miami Miller School of Medicine,
A. et al. Toxicol. In Vitro 19, 541-546 (2005)
T. et al. Exp. Clin. Endocrinol. Diabetes 108, 347-352 (2000)
B. et al. Proc. Natl. Acad. Sci. USA 107, 12623-12628 (2010)
AND INSTITUTIONS MENTIONED
Akela Pharma Inc. (TSX:AKL), Austin, Texas
Beta-O2 Technologies Ltd., Petah Tikva, Israel
Dresden University of Technology, Dresden, Germany
La Jolla Institute for Allergy & Immunology, La Jolla, Calif.
Merck KGaA (Xetra:MRK), Darmstadt, Germany
Miami VA Healthcare System, Miami, Fla.
Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark
Theratechnologies Inc. (TSX:TH; NASDAQ:THER), Montreal, Quebec, Canada
University Hospital of Carl Gustav Carus, Dresden, Germany
University of Miami, Miami, Fla.
University of Miami Miller School of Medicine, Miami, Fla.
U.S. Department of Veterans Affairs, Washington, D.C.
ViaCyte Inc., San Diego, Calif.
Wake Forest School of Medicine, Winston-Salem, N.C.